Kaplan-Meier estimates of PFS and OS of patients enrolled with untreated MCL. Median follow-up was 12.7 years. (A) The 5-year PFS of all patients was 23.1% (95% CI, 13-35). (B) The 5-year OS of all patients was 78.3% (95% CI, 64-87). (C) The 5-year PFS of patients randomly assigned to bortezomib maintenance vs observation was 14.3% (95% CI, 2-37) vs 37.5% (95% CI, 15-60; P = .39). (D) The 5-year OS of patients randomly assigned to bortezomib maintenance vs observation was 69.2% (95% CI, 37-87) vs 87.5% (95% CI, 59-97; P = .32).